Keyphrases
Phase II Study
100%
Combination Immunotherapy
100%
Irinotecan
100%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
100%
Combined Treatment
71%
Disease Progression
28%
Small Cell Lung Cancer
28%
Anti-programmed Death 1
28%
Anti-programmed death-1 Monoclonal Antibody
28%
Platinum-etoposide
28%
Clinical Trials
14%
Japan
14%
Later-line
14%
Clinical Benefit
14%
Patient's Will
14%
Monotherapy
14%
Response Rate
14%
Best Medical Treatment
14%
Previously Treated
14%
Combined Therapy
14%
Second-line Treatment
14%
UGT1A1
14%
Patient-centered
14%
Intolerance
14%
Patient Consent
14%
Overall Survival Progression-free Survival
14%
Later-line Treatment
14%
Medicine and Dentistry
Small Cell Lung Cancer
100%
Chemoimmunotherapy
100%
Irinotecan
100%
Disease Exacerbation
22%
Etoposide
22%
Programmed Death 1 Ligand 1
22%
Clinical Trial
11%
Monotherapy
11%
Progression Free Survival
11%
Overall Survival
11%
Combined Therapy
11%
Antiinfective Agent
11%
DNA Polymorphism
11%
Chemotherapy
11%
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
100%
Small Cell Lung Cancer
100%
Irinotecan
100%
Disease Exacerbation
22%
Etoposide
22%
Programmed Death 1 Ligand 1
22%
Antiinfective Agent
11%
Monotherapy
11%
Clinical Trial
11%
Overall Survival
11%
Progression Free Survival
11%